Healthy | PAH | High risk | Low risk | pvalue | |
---|---|---|---|---|---|
n=20 | n=81 | n=71 | n=10 | ||
Age, mean (std) (n) | 59.7 (8.9) (20) | 58 (11.3) (79) | 60.1 (10.8) (71) | 52.3 (10.7) (10) | 0.20 |
Sex | 0.18 | ||||
Female | 15 (75.0) | 59 (74.7) | 62 (87.3) | 9 (90.0) | |
Male | 5 (25.0) | 20 (25.3) | 9 (12.7) | 1 (10.0) | |
Race/ethnicity | <.0001 | ||||
Asian/Pacific Islander | 1 (1.3) | 1 (1.4) | 3 (30.0) | ||
Black | 12 (15.2) | 2 (2.8) | 0 | ||
Caucasian | 64 (81.0) | 60 (84.5) | 3 (30.0) | ||
Hispanic | 2 (2.5) | 5 (7.0) | 3 (30.0) | ||
Native American | 0 | 2 (2.8) | 0 | ||
Other Ethnic Origin | 0 | 1 (1.4) | 1 (10.0) | ||
SSc subtype | 0.39 | ||||
Diffuse | 20 (25.0) | 15 (21.1) | 5 (50.0) | ||
Limited | 57 (71.2) | 54 (76.1) | 5 (50.0) | ||
Unclassified | 3 (3.8) | 2 (2.8) | 0 | ||
Antibody | 0.1433 | ||||
Mixed or other | 15 (19.0) | 13 (18.6) | 0 | ||
Scl 70 | 13 (16.5) | 15 (21.4) | 2 (20.0) | ||
U1RNP | 3 (3.8) | 1 (1.4) | 0 | ||
Centromere | 20 (25.3) | 15 (21.4) | 6 (60.0) | ||
Isolated nucleolar | 20 (25.32) | 13 (18.57) | 0 | ||
Negative | 3 (3.8) | 9 (12.9) | 2 (20.0) | ||
RNA polymerase III | 5 (6.3) | 4 (5.7) | 0 | ||
FVC, median (range) (n) | 71.2 (27.1–104.8) (69.0) | 85.2 (32.5–130.6) (64.0) | 96.0 (84.0–112.0) (10.0) | <.0001 | |
DLCO, median (range) (n) | 37.0 (9.9–90.7) (67) | 50.4 (10.1–94.2) (60) | 98.5 (80.0–128.0) (10) | <.0001 | |
RVSP, median (range) (n) | 50.5 (17.0–120.0) (68) | 38.5 (23.0–80.0) (60) | 28.0 (18.0–35.0) (7) | <.0001 | |
Disease duration, years, median (range) (n) | |||||
Raynaud’s symptom | 10.2 (0.9–45.1) (75) | 10.7 (0.4–49.2) (64) | 7.3 (1.5–33.7) (9) | 0.4951 | |
Non-Raynaud’s symptom | 8.7 (0.0–33.0) (74) | 9.3 (0.1–40.9) (66) | 5.1 (1.3–15.3) (9) | 0.1644 |